United States - English - NLM (National Library of Medicine)

carilion materials management - isosorbide dinitrate (unii: ia7306519n) (isosorbide dinitrate - unii:ia7306519n) - isosorbide dinitrate tablets are indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of immediate-release oral isosorbide dinitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. isosorbide dinitrate is contraindicated in patients who are allergic to isosorbide dinitrate or any of its other ingredients. do not use isosorbide dinitrate in patients who are taking certain drugs for erectile dysfunction (phosphodiesterase inhibitors), such as sildenafil, tadalafil, or vardenafil. concomitant use can cause severe hypotension, syncope, or myocardial ischemia. do not use isosorbide dinitrate in patients who are taking the soluble guanylate cyclase stimulator riociguat. concomitant use can cause hypotension.

United States - English - NLM (National Library of Medicine)

carilion materials management - isosorbide dinitrate (unii: ia7306519n) (isosorbide dinitrate - unii:ia7306519n) - isosorbide dinitrate tablets, usp (oral) are indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of immediate-release oral isdn is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. allergic reactions to organic nitrates are extremely rare, but they do occur. isosorbide dinitrate tablets, usp (oral) are contraindicated in patients who are allergic to isdn or any of its other ingredients.

United States - English - NLM (National Library of Medicine)

carilion materials management - isosorbide dinitrate (unii: ia7306519n) (isosorbide dinitrate - unii:ia7306519n) - isosorbide dinitrate tablets, usp (oral) are indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of immediate-release oral isdn is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. allergic reactions to organic nitrates are extremely rare, but they do occur. isosorbide dinitrate tablets, usp (oral) are contraindicated in patients who are allergic to isdn or any of its other ingredients.

United States - English - NLM (National Library of Medicine)

bluepoint laboratories - isosorbide dinitrate (unii: ia7306519n) (isosorbide dinitrate - unii:ia7306519n) - isosorbide dinitrate tablets, usp are indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of immediate-release oral isosorbide dinitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. isosorbide dinitrate tablets are contraindicated in patients who are allergic to isosorbide dinitrate or any of its ingredients. do not use isosorbide dinitrate tablets in patients who are taking certain drugs for erectile dysfunction (phosphodiesterase inhibitors), such as sildenafil, tadalafil, or vardenafil. concomitant use can cause severe hypotension, syncope, or myocardial ischemia. do not use isosorbide dinitrate tablets in patients who are taking the soluble guanylate cyclase stimulator riociguat. concomitant use can cause hypotension.

United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - isosorbide dinitrate (unii: ia7306519n) (isosorbide - unii:wxr179l51s) - isosorbide dinitrate 5 mg

United States - English - NLM (National Library of Medicine)

mckesson contract packaging - isosorbide dinitrate (unii: ia7306519n) (isosorbide - unii:wxr179l51s) - isosorbide dinitrate 10 mg

United States - English - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - hydralazine hydrochloride (unii: fd171b778y) (hydralazine - unii:26nak24ls8), isosorbide dinitrate (unii: ia7306519n) (isosorbide dinitrate - unii:ia7306519n) - isosorbide dinitrate and hydralazine hydrochloride tablets are indicated for the treatment of heart failure as an adjunct to standard therapy in self-identified black patients to improve survival, to prolong time to hospitalization for heart failure, and to improve patient-reported functional status. there is little experience in patients with nyha class iv heart failure. isosorbide dinitrate and hydralazine hydrochloride tablets are contraindicated in patients who are allergic to organic nitrates. do not use isosorbide dinitrate and hydralazine hydrochloride tablets in patients who are taking pde-5 inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil. concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see drug interactions (7.1)] . do not use isosorbide dinitrate and hydralazine hydrochloride tablets in patients who are taking the soluble guanylate cyclase (sgc) stimulator riociguat. concomitant use can cause hypotension. risk summary there are no data on isosorbide

United States - English - NLM (National Library of Medicine)

wilshire pharmaceuticals - hydralazine hydrochloride (unii: fd171b778y) (hydralazine - unii:26nak24ls8), isosorbide dinitrate (unii: ia7306519n) (isosorbide dinitrate - unii:ia7306519n) - isosorbide dinitrate and hydralazine hydrochloride tablets are indicated for the treatment of heart failure as an adjunct to standard therapy in self-identified black patients to improve survival, to prolong time to hospitalization for heart failure, and to improve patient-reported functional status. there is little experience in patients with nyha class iv heart failure. isosorbide dinitrate and hydralazine hydrochloride tablets are contraindicated in patients who are allergic to organic nitrates. do not use isosorbide dinitrate and hydralazine hydrochloride tablets in patients who are taking pde-5 inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil. concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see drug interactions (7.1)] . do not use isosorbide dinitrate and hydralazine hydrochloride tablets in patients who are taking the soluble guanylate cyclase (sgc) stimulator riociguat. concomitant use can cause hypotension. risk summary there are no data on isosorbide

United States - English - NLM (National Library of Medicine)

inwood laboratories, inc. - isosorbide dinitrate (unii: ia7306519n) (isosorbide dinitrate - unii:ia7306519n) - tablet, extended release - 40 mg - isosorbide dinitrate extended-release tablets are indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of controlled-release oral isosorbide dinitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. allergic reactions to organic nitrates are extremely rare, but they do occur. isosorbide dinitrate extended-release tablets are contraindicated in patients who are allergic to isosorbide dinitrate or to any of its other ingredients.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - isosorbide mononitrate (unii: lx1oh63030) (isosorbide mononitrate - unii:lx1oh63030) - isosorbide mononitrate 30 mg - isosorbide mononitrate extended-release tablets are indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of oral ismn is not sufficiently rapid for this product to be useful in aborting an acute angina episode. isosorbide mononitrate extended-release tablets are contraindicated in patients who have shown hypersensitivity or idiosyncratic reactions to other nitrates or nitrites.